Xenotransplantation: Patient FAQ

Projects
Portfolio:
Insert Portfolio
Barrier Type:
Insert Barrier Type

This project is a collaboration between the National Kidney Foundation (NKF), Kidney Health Initiative, and the Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research. The goal of this project is to develop a patient-focused educational document explaining the fundamentals of kidney xenotransplantation. It builds on previous projects from all three organizations that identified information needs for patients considering clinical trials for kidney xenotransplantation. The FAQ translates complex concepts into clear, plain language for patients, families, and care partners. Organized around common patient questions, it will function as a living resource with updates made as evidence, clinical guidance, or policy shifts occur.

View More Projects

Workgroup

  • Laura H. Mariani – Renal Division, University of Michigan, Ann Arbor, Michigan
  • Howard Trachtman – Department of Pediatrics/Nephrology, University of Michigan, Ann Arbor, Michigan
  • Aliza Thompson – Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
  • Barbara S. Gillespie – Fortrea, Durham, North Carolina; Kidney Center, University of North Carolina, Chapel Hill, North Carolina
  • Michelle Denburg – Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
  • Ulysses Diva – Travere Therapeutics, San Diego, California
  • Duvuru Geetha – School of Medicine, Johns Hopkins University, Baltimore, Maryland
  • Peter J. Greasley – Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Michelle A. Hladunewich – University of Toronto, Toronto, Ontario
  • Robert B. Huizinga – Aurinia Pharmaceuticals, Victoria, British Columbia, Canada
  • Jula K. Inrig  – Travere Therapeutics, San Diego, California
  • Radko Komers – Travere Therapeutics, San Diego, California
  • Louis-Philippe Laurin – Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
  • Dustin J. Little – Clinical Development, Late Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, Maryland
  • Patrick H. Nachman – University of Minnesota, Minneapolis, Minnesota
  • Kimberly A. Smith – Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
  • Liron Walsh – Goldfinch Bio, Boston, Massachusetts
  • Keisha L. Gibson – Kidney Center, University of North Carolina, Chapel Hill, North Carolina